Philippine Drug Price Controls Pinch Brands And Generics
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - State-mandated price cuts in the Philippines on branded drugs are putting some generics makers in a tight spot. The government price controls, which began in August 2009, have spread swiftly, and the caps affecting commonly prescribed drugs are now pressuring their generic competitors
You may also be interested in...
Aim To Cut Drug Prices By Asian Governments May Backfire, Discourage Investment – IMS
Efforts by Asian governments to reduce drug prices may have little impact on healthcare provision and may in fact backfire by driving some drugs out of the market.
PhamAsia News Top Editors' Picks Of 2010
More outsourcing of clinical trials and manufacturing to Asia continued in 2010 as both U.S. and European pharma companies allocated more resources to emerging markets where growth is expected to remain in the double digits for the next five years. At the same time, more M&As and consolidation occurred in a frantic search for innovation that will likely continue. As patents begin to expire, readers can expect many Asian companies to grab the spotlight with biosimilar strategies increasingly coming out of Asia